Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04869813 · ClinicalTrials.gov registry record

Sarcopenia Magnetic Resonance Imaging Evaluation (SUSIE)

A clinical trial of Sarcopenia, sponsored by The Cleveland Clinic.

Recruiting
Registry status
70
Enrollment target
1
Study location

NCT04869813 is a study of Sarcopenia that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 70 participants, below the 79-participant average among 41 other Sarcopenia trials with a reported enrollment target (11% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04869813, a study of Sarcopenia, is actively recruiting participants, sponsored by The Cleveland Clinic.

RECRUITING
Registry status
70 participants
Enrollment target
1
Study location

Study Summary

The goal of the proposed research is to investigate Magnetic Resonance (MR) Fingerprinting and P-MRS (Phosphorus-31 MR Spectroscopy) imaging for characterization of skeletal muscle in heart failure patients with sarcopenia. Heart failure patients with and without sarcopenia will be scanned using MR Fingerprinting and an existing Post-exercise phosphocreatine (PCr) recovery MR imaging protocol to obtain characteristic profiles of quantitative T1, T2, and PCr recovery rate.

Conditions Studied

Study Locations (1)

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 70 participants
Start Date 2021-04-09
Est. Completion 2026-12-31

Sponsor

The Cleveland Clinic

688 total trials

What the Registry Record Tells You About NCT04869813

The ClinicalTrials.gov registry entry for NCT04869813 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 79-participant average among 41 other Sarcopenia trials with a reported enrollment target (11% lower). The listed sponsor is The Cleveland Clinic, which has 688 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Sarcopenia appearing as the primary indexed condition, and to 0 interventions.

NCT04869813 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT04869813 about?

NCT04869813 is a clinical study titled "Sarcopenia Magnetic Resonance Imaging Evaluation (SUSIE)". The goal of the proposed research is to investigate Magnetic Resonance (MR) Fingerprinting and P-MRS (Phosphorus-31 MR Spectroscopy) imaging for characterization of skeletal muscle in heart failure patients with sarcopenia. Heart failure patients with and without sarcopenia will be scanned using MR ...

What is the current status of trial NCT04869813?

This trial is currently recruiting. The enrollment target is 70 participants. The study started on 2021-04-09. Estimated completion is 2026-12-31.

What conditions does trial NCT04869813 study?

This clinical trial studies the following conditions: Sarcopenia.

Who is sponsoring clinical trial NCT04869813?

This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04869813 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Sarcopenia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.